Stock Ratings / Health Care / NBTX / insiders

STOK (59) KLRA (50) CMPS (37) QURE (52) ⌘ Pro Terminal →

Nanobiotix S.A. (NBTX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$33.80 -0.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Nanobiotix S.A. (NBTX) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.72B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NBTX)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

NBTX Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (NBTX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on NBTX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NBTX)

✓Walkthrough of NBTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NBTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.37%⚡ TESTING RESISTANCE

2026-10-30O $32.50H $33.80L $31.10C $33.80VOL 235.7K

RES: $33.91SUP: $18.69SMA50: $32.53SMA200: $33.85

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NBTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NBTX Butterfly Map → + Track NBTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NBTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NBTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NBTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NBTX)

Health Care Rank #317 of 1016 ⚔️ STOK vs NBTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NBTX vs. STOK, KLRA, CMPS, QURE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nanobiotix S.A. (NBTX) ranks #317 by composite RQD confidence (52/100, grade D+) and #285 by equity capitalization ($1.72B). Within this direct 5-issuer industry benchmark cohort, NBTX leads on earnings valuation at N/A trailing P/E, while STOK leads on capital efficiency and profitability with -6.1% ROIC and — gross margin. STOK currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with NBTX at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NBTX ACTIVE Nanobiotix S.A.	D+	52/100	—	—	—	-0.53%	$1.72B	Benchmark Subject
STOK Stoke Therapeutics Inc.	C-	59/100	—	—	-6.1%	-0.23%	$1.70B	/stok-vs-nbtx →
KLRA Kailera Therapeutics Inc.	D	50/100	—	—	—	-0.07%	$1.74B	/klra-vs-nbtx →
CMPS COMPASS Pathways Plc American Depository Shares	D-	37/100	—	—	-35.0%	-0.73%	$1.69B	/cmps-vs-nbtx →
QURE uniQure N.V.	D+	52/100	—	—	-35.0%	+1.32%	$1.75B	/qure-vs-nbtx →

2. NBTX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Nanobiotix S.A. (NBTX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.72B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. NBTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NBTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nanobiotix S.A. (NASDAQ: NBTX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $33.80 (-0.53% 1D, market cap $1.72B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NBTX ranks #317 in composite RQD confidence.

How does NBTX compare to STOK and KLRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NBTX carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, STOK (Stoke Therapeutics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC -6.1%, cap $1.70B) and KLRA (Kailera Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC —, cap $1.74B). Among the 5-stock peer group, NBTX leads on earnings multiple (N/A) while STOK leads on capital efficiency (-6.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NBTX?

For Nanobiotix S.A. (NBTX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #317 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NBTX trading relative to its 50-day, 200-day, and 52-week technical levels?

NBTX last traded at $33.80 (-0.53% on volume of 85,586 shares), positioning the stock +3.90% above its 50-day simple moving average ($32.53) and -0.15% below its 200-day simple moving average ($33.85). Across its 52-week range of $17.42 to $57.14, NBTX sits at the 41.2% percentile with a 14-day RSI of 55.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($29.58 to $38.02).

NBTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are NBTX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies NBTX leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: NBTX RQD Cockpit NBTX 12M Forecast NBTX Earnings & Move NBTX Dividends & DRIP NBTX Insiders & 13F NBTX Whale Options NBTX Profit Sankey NBTX News & Why